Categories: News

SCYNEXIS to Report Second Quarter 2022 Financial results and Provide a Corporate Update on August 15

JERSEY CITY, N.J., Aug. 09, 2022 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at 8:30 a.m. EDT on Monday, August 15, 2022 to provide a corporate update and discuss the Company’s financial results for the second quarter ended June 30, 2022.

Conference call and webcast details:

Investors (domestic): (877) 704-4453
Investors (international): (201) 389-0920
Webcast:  https://viavid.webcasts.com/starthere.jsp?ei=1555622&tp_key=54aa49f539
Conference ID: 13730704

A live audio webcast can be accessed by visiting the Investor Relations section of the Company’s website, www.scynexis.com. A replay of the webcast will be archived on the SCYNEXIS website for 90 days following the event.

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS scientists are developing the company’s lead asset, ibrexafungerp, as a broad-spectrum, systemic antifungal for multiple fungal indications in both the community and hospital settings. SCYNEXIS launched its first commercial product in the U.S., BREXAFEMME® (ibrexafungerp tablets). The U.S. Food and Drug Administration (FDA) approved BREXAFEMME on June 1, 2021. In addition, clinical investigation and development of oral ibrexafungerp for the prevention of recurrent vulvovaginal candidiasis (VVC) and the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing. For more information, visit www.scynexis.com.

CONTACT
Investor Relations
Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
ikoffler@lifesciadvisors.com

Media Relations
Debbie Etchison
Debbie.etchison@scynexis.com

Staff

Recent Posts

American College of Osteopathic Family Physicians Announces 2024-2025 Board of Governors

CHICAGO, IL / ACCESSWIRE / April 3, 2024 / The American College of Osteopathic Family…

5 hours ago

ACOFP Foundation Announces New Campaign, Family Medicine Forward

Campaign underscores the urgency and need to support early career osteopathic family physicians.CHICAGO, IL /…

8 hours ago

Reveal Lasers Reports First Quarter With Record-Breaking 300% Growth

LAS VEGAS, NV / ACCESSWIRE / April 3, 2024 / Reveal Lasers, a burgeoning force…

11 hours ago

Weave Enhances Integration with DrChrono by EverHealth

Deeper integration unlocks powerful Weave features to improve patient experiencesLEHI, Utah--(BUSINESS WIRE)--Weave (NYSE: WEAV), a…

14 hours ago

Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature

CAMBRIDGE, MA / ACCESSWIRE / April 3, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that…

14 hours ago

LPW Training Services Awarded the Association for Talent Development’s Excellence in Practice for 2024

SOMERVILLE, NJ / ACCESSWIRE / April 3, 2024 / LPW Training Services, a global industry…

14 hours ago